Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Find the Achilles’ Heel: Sitting Down With Amy Jensen-Smith
SOTIO Biotech’s CSO explains why drug developers should test their weakest assumptions early, how she builds innovative teams, and where ADCs could go next
Clinical Scorecard: Amy Jensen-Smith on ADC Development and Scientific Leadership
At a Glance
Category
Detail
Condition
Antibody-drug conjugate (ADC) development for solid tumors
Key Mechanisms
ADCs combine a tumor-recognizing antibody with potent chemotherapy intended to deliver the chemotherapy directly to the tumor.
Target Population
Patients with solid tumors; specific patient groups are not identified.
Care Setting
Preclinical oncology drug discovery and development, with programs advanced toward clinical readiness.
Key Highlights
SOTIO develops ADCs for solid tumors, and its CSO oversees the preclinical pipeline from target and technology ideas through preparation for clinical development.
Jensen-Smith says drug candidates should align target biology, disease context, and the needs of the intended patient population.
For novel targets, SOTIO prioritizes the most critical question and tests it early to identify programs that should be discontinued or advanced.
She describes biotech as offering a balance of resources, focus, and freedom for innovative research, based on her experience.
She recommends building teams with varied backgrounds and work styles, making room for failure, and listening to team members.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
No patient-level or prescribing data are reported. The interview concerns SOTIO’s preclinical ADC development for solid tumors.
The interview describes ADCs as antibodies linked to potent chemotherapy and provides no dosing, safety, or efficacy data.
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss new antibody drug conjugate treatment options in first line triple negative breast cancer.
